Filtered By:
Condition: Thrombosis
This page shows you your search results in order of date. This is page number 16.
Order by Relevance | Date
Total 39135 results found since Jan 2013.
Low-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
Korean J Intern Med. 2023 Sep;38(5):583-594. doi: 10.3904/kjim.2023.035. Epub 2023 Sep 1.ABSTRACTIn the last decade, non-vitamin K antagonist oral anticoagulants (NOACs), a new generation of OACs, were introduced to prevent thromboembolism in patients with atrial fibrillation. Although vitamin K-dependent anticoagulants have long been used as OACs, their inherent disadvantage of considerable bleeding complications has limited their use. NOACs demonstrate similar or superior clinical outcomes to those of warfarin. Although strict dose reduction criteria are recommended for NOACs, low-dose NOACs are frequently utilized, espe...
Source: The Korean Journal of Internal Medicine - September 8, 2023 Category: Internal Medicine Authors: Ki Hong Lee Hyung Wook Park Source Type: research
Performance, safety, and biocompatibility of a novel PFO closure device in a long-term porcine model
CONCLUSIONS: In the standard porcine model, device retention and biocompatibility remained favorable following structural and functional device modifications exemplified by the second-generation PFO occluder from Encore Medical, including marked reduction of metal mass.PMID:37684005 | DOI:10.1016/j.jjcc.2023.09.001
Source: Journal of Cardiology - September 8, 2023 Category: Cardiology Authors: Mateusz Kachel Pedro Melo Karl Van Wygerden Yanping Cheng Michael Corcoran David S Garlick Michelle Olson Christopher D Nielsen Juan F Granada Grzegorz L Kaluza Source Type: research
Low-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
Korean J Intern Med. 2023 Sep;38(5):583-594. doi: 10.3904/kjim.2023.035. Epub 2023 Sep 1.ABSTRACTIn the last decade, non-vitamin K antagonist oral anticoagulants (NOACs), a new generation of OACs, were introduced to prevent thromboembolism in patients with atrial fibrillation. Although vitamin K-dependent anticoagulants have long been used as OACs, their inherent disadvantage of considerable bleeding complications has limited their use. NOACs demonstrate similar or superior clinical outcomes to those of warfarin. Although strict dose reduction criteria are recommended for NOACs, low-dose NOACs are frequently utilized, espe...
Source: The Korean Journal of Internal Medicine - September 8, 2023 Category: Internal Medicine Authors: Ki Hong Lee Hyung Wook Park Source Type: research
Performance, safety, and biocompatibility of a novel PFO closure device in a long-term porcine model
CONCLUSIONS: In the standard porcine model, device retention and biocompatibility remained favorable following structural and functional device modifications exemplified by the second-generation PFO occluder from Encore Medical, including marked reduction of metal mass.PMID:37684005 | DOI:10.1016/j.jjcc.2023.09.001
Source: Journal of Cardiology - September 8, 2023 Category: Cardiology Authors: Mateusz Kachel Pedro Melo Karl Van Wygerden Yanping Cheng Michael Corcoran David S Garlick Michelle Olson Christopher D Nielsen Juan F Granada Grzegorz L Kaluza Source Type: research
Adverse events associated with amplatzer left atrial appendage occlusion delivery system: A Food and Drug Administration MAUDE database study
ConclusionLAAO-related adverse events are increasingly being reported using the Amplatzer LAAO delivery sheath. It is anticipated that improvements in device technology, the advent of steerable sheaths, and operator experience will minimize these complications.
Source: Journal of Cardiovascular Electrophysiology - September 8, 2023 Category: Cardiology Authors: Jakrin Kewcharoen,
Kuldeep Shah,
Rahul Bhardwaj,
Tahmeed Contractor,
Mohit K. Turagam,
Ravi Mandapati,
Dhanunjaya Lakkireddy,
Jalaj Garg Tags: BRIEF COMMUNICATION Source Type: research
Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis
CONCLUSIONS: Recruitment targets were reached, but many eligible participants declined randomization. There were numerically more bleeding events in patients taking rivaroxaban compared with control, but rates of bleeding and recurrent venous thromboembolism were low overall and in keeping with previous studies. Participants had symptoms affecting their well-being at enrollment but improved over time.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT03178864.PMID:37675613 | DOI:10.1161/STROKEAHA.123.044113
Source: Atherosclerosis - September 7, 2023 Category: Cardiology Authors: Thalia S Field Vanessa Dizonno Mohammed A Almekhlafi Fouzi Bala Ibrahim Alhabli Hubert Wong Monica Norena Maria Karina Villaluna Princess King-Azote Namali Ratnaweera Steven Mancini Stephen C Van Gaal Laura K Wilson Brett R Graham Luciano A Sposato Dylan Source Type: research
PAR4 Inhibition Reduces Coronary Artery Atherosclerosis and Myocardial Fibrosis in SR-B1/LDLR Double Knockout Mice
CONCLUSIONS: The PAR4 inhibitory RAG8 pepducin reduced coronary artery atherosclerosis and myocardial fibrosis in SR-B1/LDLR double knockout mice fed a high-fat, high-cholesterol diet containing cholate. Furthermore, RAG8 reduced VCAM-1 in nonatherosclerotic coronary arteries and reduced leukocyte and platelet accumulation in atherosclerotic coronary arteries. These findings identify PAR4 as an attractive target in reducing coronary artery disease development, and the use of RAG8 may potentially be beneficial in cardiovascular disease.PMID:37675637 | DOI:10.1161/ATVBAHA.123.319767
Source: Arteriosclerosis, Thrombosis and Vascular Biology - September 7, 2023 Category: Cardiology Authors: Samuel K Lee Rida Malik Ji Zhou Wei Wang Peter Gross Jeffrey Weitz Rithwik Ramachandran Bernardo L Trigatti Source Type: research
Angiogenesis Redux: An Overall Protective Role of VEGF/KDR Signaling in the Microvasculature in Pulmonary Arterial Hypertension
Arterioscler Thromb Vasc Biol. 2023 Sep 7. doi: 10.1161/ATVBAHA.123.319839. Online ahead of print.NO ABSTRACTPMID:37675636 | DOI:10.1161/ATVBAHA.123.319839
Source: Arteriosclerosis, Thrombosis and Vascular Biology - September 7, 2023 Category: Cardiology Authors: Ying Zhong Paul B Yu Source Type: research
Transcriptomic Profiling Identifies Ferroptosis-Related Gene Signatures in Ischemic Muscle Satellite Cells Affected by Peripheral Artery Disease
CONCLUSIONS: This is the first report documenting that genes known to be involved in ferroptosis are differentially expressed in human skeletal muscle affected by PAD. Targeting ferroptosis may be a novel therapeutic strategy to reduce PAD myopathy.PMID:37675635 | DOI:10.1161/ATVBAHA.123.319518
Source: Arteriosclerosis, Thrombosis and Vascular Biology - September 7, 2023 Category: Cardiology Authors: Lillian Tran Bowen Xie Edwyn Assaf Ricardo Ferrari Iraklis I Pipinos George P Casale Roberto Ivan Mota Alvidrez Simon Watkins Ulka Sachdev Source Type: research
Diversity of Megakaryocytes
Arterioscler Thromb Vasc Biol. 2023 Sep 7. doi: 10.1161/ATVBAHA.123.318782. Online ahead of print.ABSTRACTMegakaryocytes are commonly known as large, polyploid, bone marrow resident cells that contribute to hemostasis through the production of platelets. Soon after their discovery in the 19th century, megakaryocytes were described in tissue locations other than the bone marrow, specifically in the lungs and the blood circulation. However, the localization of megakaryocytes in the lungs and the contribution of lung megakaryocytes to the general platelet pool has only recently been appreciated. Moreover, the conception of me...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - September 7, 2023 Category: Cardiology Authors: Florian Puhm Audr ée Laroche Eric Boilard Source Type: research
Unanticipated Enhancement of Intestinal TG Output by Apoc3 ASO Inhibition
CONCLUSIONS: Despite the marked reduction in plasma triglyceride concentration that occurs with apoC3 ASO inhibition, intestinal triglyceride output surprisingly increased rather than decreased. These data demonstrate that the reduction of intestinal triglyceride output does not contribute to the potent plasma triglyceride-lowering observed with this novel therapy for hypertriglyceridemia. Further studies are required to explore the mechanism of this intestinal effect.PMID:37675633 | DOI:10.1161/ATVBAHA.123.319765
Source: Arteriosclerosis, Thrombosis and Vascular Biology - September 7, 2023 Category: Cardiology Authors: Majid Mufaqam Syed-Abdul Lili Tian Gary F Lewis Source Type: research
Providing End-of-Life Care in the Community: What Are the Challenges in Malaysia?
J Hosp Palliat Care. 2022 Sep 1;25(3):133-137. doi: 10.14475/jhpc.2022.25.3.133.ABSTRACTA 72-year-old woman with metastatic lung cancer to bone and brain and with left external iliac vein thrombosis was under the care of a community palliative care provider. She experienced an acute pain crisis due to acute limb ischemia of the left lower limb. Goals-of-care discussions were held with the patient and her family; she prioritized symptom control and end-of-life care at home. The family and patient were aware of her short prognosis. Her complex pain was managed by the community palliative team, and her family was empowered to...
Source: Cancer Control - September 7, 2023 Category: Cancer & Oncology Authors: Yoke Yeng Leong Ednin Hamzah Sylvia McCarthy Zee Nee Lim Source Type: research
